Real Hope For Cancer Patients | Precision Biologics

UNIQUE DISCOVERY PLATFORM

realize our potential

LEARN MORE

We have a platform of patient tumor
derived anticancer vaccines.

THERAPEUTICS

leaders in biotherapeutics

LEARN MORE

Our unique platform, combined with breakthroughs in biotechnology, enable us to produce targeted antibodies that weren’t possible just a few years ago.

COMPANION DIAGNOSTICS

explore our program

LEARN MORE

Our monoclonal antibodies are designed to target the tumor without harming healthy cells.

Precision Biologics is dedicated to improving the lives of cancer patients through its innovative therapeutic and diagnostic products.

Precision Biologics to give presentation at CICON 2023, Milan, Italy - shares new NEO-201 data from current Phase 2 Clinical Trial

DATE: September 18, 2023

AACR 2023 – Poster presentation in person, Orlando, FL, Orange County Convention Center, Tuesday, April 18th, 2023

DATE: April 13, 2023

Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201

DATE: April 6, 2023

Dr. Philip M. Arlen gives keynote address on NEO-201 Developments at World Antibody Congress, San Diego, CA, March 20th, 2023

DATE: March 14, 2023

SITC 2022 - Posters will be presented in person at the Boston Convention & Exhibition Center on Thursday, November 10th, 2022

DATE: November 9, 2022

Dr. Philip M. Arlen gives presentation on recent NEO-201 clinical development at Biomarkers & Immuno US, 4th Annual Advances in Immuno-Oncology USA Congress, San Diego, CA, October 4, 2022

DATE: October 4, 2022

# of people living with cancer in the US

annual # of new cases of cancer in the US

annual # of deaths from cancer in the US